AB0752 Efficacy and Safety of Brodalumab over One Year in Patients with Psoriatic Arthritis with and without Prior Exposure to A Biologic

Background New agents with novel mechanisms of action are needed to treat the growing pool of patients with psoriatic arthritis (PsA) who do not respond to, lose response to, or do not tolerate biologics. Patients with PsA who fail one tumor necrosis factor inhibitor (TNFi) often demonstrate reduced...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Annals of the rheumatic diseases 2014-06, Vol.73 (Suppl 2), p.1052-1053
Hauptverfasser:	Genovese, M.C., Mease, P.J., Greenwald, M.W., Ritchlin, C.T., Beaulieu, A.D., Deodhar, A., Newmark, R., Feng, J., Erondu, N., Nirula, A.
Format:	Artikel
Sprache:	eng
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!